Parkinson’s Disease (PD) is widely known as a neurological disorder that affects movement, but many people are surprised to learn that it doesn’t only impact older adults. When symptoms begin before the age of 50, the condition is called Early Onset Parkinson’s Disease (EOPD). Although less common than later life PD, EOPD carries unique challenges for those diagnosed, their families, and caregivers.
In recent years, the healthcare world has witnessed explosive growth in the use of digital technologies, from wearable devices to app‑based monitoring tools. A new study published in Communications Medicine explores this transformation in depth, examining both the opportunities and the challenges of using digital biomarkers to improve patient care and reshape clinical research.
When you or someone you love lives with Parkinson’s Disease (PD), it’s natural to wonder what things, big or small, might improve long‑term health. A recent study looked at something simple yet important: vitamin intake, specifically folate (B9), vitamin B6, and vitamin B12.
Parkinson’s Disease affects more than 10 million people worldwide and remains one of the most challenging neurodegenerative disorders to diagnose, treat, and manage. While current treatments can ease symptoms, none can halt or reverse the disease. But a groundbreaking study published in Nature on February 4, 2026, may mark a turning point in our understanding of the disorder’s root causes, and open the door to far more effective, non‑invasive treatments.
Parkinson’s Disease is often described as a condition where dopamine‑producing neurons slowly die off, but why these neurons are lost has remained one of the biggest unanswered questions in neuroscience. While researchers have long suspected the brain’s immune system plays a role, the exact mechanism has been difficult to pin down.
When we think about Parkinson’s Disease, we often focus on the tremors, stiffness, and slowed movement that shape daily life. But beneath those visible symptoms lies a quieter process: the brain’s struggle to clear out toxic proteins that contribute to neurodegeneration. A newly published study in npj Parkinson’s Disease explores a surprising possible helper in this fight, carbon dioxide, delivered in short, controlled bursts.
